Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

Dow:

Nasdaq:

S&P 500:

IKT

$1.557.19%-0.12

Dopo l'orario di chiusura: 1.53-0.02 -1.29%

Inhibikase Therapeutics Inc (IKT)

Date: O: H: L: C: Vol:

Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie

Form 4 Inhibikase Therapeutics Inc: Scott M. Wasserman (Director) For: 19 October - Investing.com Canada

Form 4 Inhibikase Therapeutics Inc: Scott M. Wasserman (Director) For: 19 October - Investing.com UK

A director receives 310,000 options at Inhibikase Therapeutics (IKT), with service-based vesting. - Stock Titan

Form 4 Inhibikase Therapeutics Inc: Scott M. Wasserman (Director) For: 19 October By Investing.com - Investing.com South Africa

Form 8K Inhibikase Therapeutics Inc For: 20 October By Investing.com - Investing.com South Africa

Form 8K Inhibikase Therapeutics Inc For: 20 October By Investing.com - Investing.com Canada

A cardiologist with more than two decades helping develop medicines joins Inhibikase’s board. - Stock Titan

Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors - Yahoo Finance

Inhibikase Therapeutics (IKT) Gains 4.86% to $1.73 as Buyers Test Resistance - AI Trade Signals - https://www.dars.gov.et/

IKT S-8 & SEC Filings - Yahoo Finance Australia

Chardan initiates Inhibikase Therapeutics stock with neutral rating - Investing.com

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Two new hires receive options to buy up to 128,000 Inhibikase shares - Stock Titan

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Inhibikase advances IKT-001 in pivotal PAH Phase 3 - TipRanks

Inhibikase updates corporate presentation, highlights Phase 3 IKT-001 program and timelines - TradingView

Inhibikase (NASDAQ: IKT) tests PAH pill in pivotal global trial - Stock Titan

IKT News | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Inhibikase Therapeutics (IKT) Advances 3% as Shares Test Key Resistance Zone - MFI Overbought - dars.gov.et

Inhibikase Therapeutics (NASDAQ:IKT) Stock Price Down 4.1% - What's Next? - MarketBeat

Inhibikase Therapeutics Appoints Deloitte & Touche LLP After Dismissing CohnReznick LLP as Auditor - Kalkine Media

Inhibikase (IKT) Chart: Adds 1.70% to Close at $2.39 in Latest Trading; Trading Range: the Supplied Trading Band Runs From $2.27 to $2.51 for the Current Session - Fibonacci Extension - siam.in

Inhibikase (IKT) Chart: Adds 1.70% to Close at $2.39 in Latest Trading; Trading Range: the Supplied Trading Band Runs From $2.27 to $2.51 for the Current Session - Donchian Channel - vinanet.vn

Inhibikase (IKT) Q1 2026 Results: EPS Prints Above Forecast; Post-Earnings: Shares Finish 0.42% Higher at the Close - Free Cash Flow Trends - vinanet.vn

Inhibikase Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25 - Shakeout Pattern - vinanet.vn

Inhibikase Loss Widens as Phase 3 PAH Trial Expands - MyChesCo

Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25 - Call Dominated - dars.gov.et

Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 Resistance - Reversal Setup Alerts - vinanet.vn

IKT Q1 2026 Earnings: Narrower Loss of $0.10 Per Share Beats Estimates as Pre-Revenue Biotech Holds Steady - EPS Surprise History - vinanet.vn

Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares - Stock Titan

Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares - Stock Titan

IKT Q1 2026 Earnings: Narrower-than-Expected Loss Despite Modest Share Pullback - Negative Surprise Momentum - vinanet.vn

Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants - Stock Titan

Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth - TipRanks

Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingView

Is Inhibikase Therapeutics Inc (IKT) Positioned for Growth After Reporting $0.11 Loss? GF Score: 36/100 - GuruFocus

LifeSci Capital Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Inhibikase grants $2.03 stock options to seven new hires - scanx.trade

Inhibikase Q2 EPS of $(0.11) meets analyst consensus estimates - scanx.trade

Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - Yahoo Finance

Inhibikase Therapeutics (IKT) Earnings Date and Reports 2026 $IKT - MarketBeat

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewswire

IKT S-8 & SEC Filings - Yahoo Finance Australia

Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview - TradingView

Simile a IKT

NVCT$18.480.48%

ZVRA$10.280.77%